RT Journal Article
SR Electronic
T1 Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
JF Science Advances
JO Sci Adv
FD American Association for the Advancement of Science
SP eaaz8985
DO 10.1126/sciadv.aaz8985
VO 6
IS 18
A1 Wang, Feihu
A1 Xu, Dongqing
A1 Su, Hao
A1 Zhang, Weijie
A1 Sun, Xuanrong
A1 Monroe, Maya K.
A1 Chakroun, Rami W.
A1 Wang, Zongyuan
A1 Dai, Wenbing
A1 Oh, Richard
A1 Wang, Han
A1 Fan, Qin
A1 Wan, Fengyi
A1 Cui, Honggang
YR 2020
UL http://advances.sciencemag.org/content/6/18/eaaz8985.abstract
AB Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune system to combat cancer. However, only a fraction of patients can directly benefit from the anti–programmed cell death protein 1 (aPD1) therapy, and the treatment often leads to immune-related adverse effects. In this context, we developed a prodrug hydrogelator for local delivery of ICBs to boost the host’s immune system against tumor. We found that this carrier-free therapeutic system can serve as a reservoir for extended tumoral release of camptothecin and aPD1 antibody, resulting in an immune-stimulating tumor microenvironment for boosted PD-1 blockade immune response. Our in vivo results revealed that this combination chemoimmunotherapy elicits robust and durable systemic anticancer immunity, inducing tumor regression and inhibiting tumor recurrence and metastasis. This work sheds important light into the use of small-molecule prodrugs as both chemotherapeutic and carrier to awaken and enhance antitumor immune system for improved ICBs therapy.